Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 2.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 147,048 shares of the company’s stock after selling 3,436 shares during the quarter. Great Lakes Advisors LLC owned approximately 0.26% of Protagonist Therapeutics worth $4,061,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Quantbot Technologies LP acquired a new position in Protagonist Therapeutics during the second quarter worth $76,000. Jane Street Group LLC lifted its stake in Protagonist Therapeutics by 273.3% in the 3rd quarter. Jane Street Group LLC now owns 10,289 shares of the company’s stock valued at $87,000 after buying an additional 7,533 shares in the last quarter. Ensign Peak Advisors Inc lifted its stake in Protagonist Therapeutics by 14.9% in the 3rd quarter. Ensign Peak Advisors Inc now owns 12,270 shares of the company’s stock valued at $103,000 after buying an additional 1,590 shares in the last quarter. American Century Companies Inc. acquired a new stake in Protagonist Therapeutics in the 4th quarter worth about $121,000. Finally, Principal Financial Group Inc. increased its stake in Protagonist Therapeutics by 13.4% during the 4th quarter. Principal Financial Group Inc. now owns 11,738 shares of the company’s stock worth $128,000 after buying an additional 1,389 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Trading Up 2.6 %

Protagonist Therapeutics stock opened at $17.24 on Tuesday. The company has a 50-day moving average price of $16.11 and a 200 day moving average price of $20.63. Protagonist Therapeutics, Inc. has a 12-month low of $7.24 and a 12-month high of $30.10. The stock has a market cap of $994.37 million, a P/E ratio of -6.58 and a beta of 1.85.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Thursday, November 2nd. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.10. As a group, analysts forecast that Protagonist Therapeutics, Inc. will post -1.76 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PTGX. Capital One Financial started coverage on Protagonist Therapeutics in a research report on Monday, October 30th. They set an “overweight” rating and a $32.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, October 10th. StockNews.com cut shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. JPMorgan Chase & Co. decreased their target price on shares of Protagonist Therapeutics from $36.00 to $34.00 and set an “overweight” rating on the stock in a research note on Monday, September 25th. Finally, JMP Securities upped their price target on Protagonist Therapeutics from $35.00 to $37.00 and gave the company a “market outperform” rating in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $35.25.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease.